The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Bard Luippold, CFA, is a financial analyst with experience in economic and currency forecasting, valuation of assets and closely held companies, strategic and competitive analysis, and market research. Bard is currently Corporate Finance Manager at Meracord LLC. He graduated with honors from Stanford University, has earned the right to use the CFA designation, and is a licensed Escrow Officer in Washington State. He lives with his family in Tacoma, WA.
Disclaimer: Bard Luippold is Corporate Finance Manager at Meracord LLC ("Meracord"). Articles prepared by Mr. Luippold constitute an outside business activity. As such, Meracord does not review or approve materials presented herein. The opinions and any recommendations expressed in this article are those of the author and do not reflect the opinions or recommendations of Meracord.
None of the information or opinions expressed by Mr. Luippold in his articles constitute a solicitation for the purchase or sale of any security or other instrument. Nothing Mr. Luippold's articles constitute investment advice and any recommendations that may be contained therein have not been based upon a consideration of the investment objectives, financial situation or particular needs of any specific recipient. Any purchase or sale activity in any securities or other instrument should be based upon your own analysis and conclusions. Past performance is not indicative of future results.